Anaplastic large cell lymphoma, ALK-positive.
暂无分享,去创建一个
K. Savage | S. Pileri | A. Ferreri | S. Govi
[1] A. Ewton,et al. Hepatosplenic T-cell lymphoma. , 2014, Blood.
[2] S. Pileri,et al. Anaplastic large-cell lymphoma. , 2011, Seminars in diagnostic pathology.
[3] H. Moritake,et al. C‐MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C‐MYC , 2011, American journal of hematology.
[4] R. Advani,et al. Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma , 2010 .
[5] P. Gaulard,et al. Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA) , 2010 .
[6] John P Leonard,et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.
[7] Marc Ladanyi,et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.
[8] Enzo Medico,et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B. Martínez-Delgado,et al. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. , 2009, Critical reviews in oncology/hematology.
[10] D. Ramies,et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Medeiros,et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. , 2009, Cancer research.
[12] S. Perkins,et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941 , 2009, Pediatric blood & cancer.
[13] Florian Steinberg,et al. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. , 2009, Neoplasia.
[14] Gudrun Schleiermacher,et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.
[15] D. Gary Gilliland,et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.
[16] M. Ozdemirli,et al. HIV-associated anaplastic large cell lymphoma: a report of three cases. , 2008, AIDS.
[17] Stefano A Pileri,et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.
[18] Pek-Lan Khong,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies , 2008, Annals of Hematology.
[19] G. Inghirami,et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination , 2008, Nature Medicine.
[20] C. Volteau,et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Briones,et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] A. Iafrate,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.
[23] R. Gascoyne,et al. Genomic profiling reveals different genetic aberrations in systemic ALK‐positive and ALK‐negative anaplastic large cell lymphomas , 2008, British journal of haematology.
[24] K. Ohtomo,et al. FDG-PET in T-cell and NK-cell neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[26] S. Ansell,et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Rodríguez,et al. New treatment concepts in diffuse large B-cell lymphomas (DLBL): chemothe-rapy and biological therapy. , 2007, Reviews on recent clinical trials.
[28] P. Gaulard,et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. , 2007, Blood.
[29] V. Soumelis,et al. From plasmacytoid to dendritic cell: Morphological and functional switches during plasmacytoid pre‐dendritic cell differentiation , 2006, European journal of immunology.
[30] T. Barbui,et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation , 2006, Leukemia.
[31] E. Campo,et al. ALK-Positive Anaplastic Large Cell Lymphoma Mimicking Nodular Sclerosis Hodgkin's Lymphoma: Report of 10 Cases , 2006, The American journal of surgical pathology.
[32] Nicola Pimpinelli,et al. WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.
[33] A. Rosenwald,et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. , 2005, Human pathology.
[34] P. de Paepe,et al. Successful treatment with allogeneic bone marrow transplantation of an early relapse of ALK-positive anaplastic large cell lymphoma. , 2005, Haematologica.
[35] D. Weisenburger,et al. Towards understanding the peripheral T-cell lymphomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] B. Nathwani,et al. T-Cell Lymphoma in HIV-Infected Patients , 2004, Journal of acquired immune deficiency syndromes.
[37] M. Boccadoro,et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] E. Iannitto,et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.
[39] Y. Shyr,et al. Histology Impacts the Outcome of Peripheral T-Cell Lymphomas after High Dose Chemotherapy and Stem Cell Transplant , 2004, Leukemia & lymphoma.
[40] V. Diehl,et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. , 2003, Blood.
[41] J. Macías,et al. Bone involvement and abcess formation by neutrophil-rich CD30+ anaplastic large-cell lymphoma mimicking skeletal infection in an AIDS patient. , 2003, The Journal of infection.
[42] M. Crump,et al. Autologous stem cell transplant for relapsed and refractory peripheral T‐cell lymphoma: variable outcome according to pathological subtype , 2003, British journal of haematology.
[43] V. Diehl,et al. The human anti-CD 30 antibody 5 F 11 shows in vitro and in vivo activity against malignant lymphoma ( Short title : Fully human anti-CD 30 antibody ) , 2003 .
[44] V. Diehl,et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] G. Krieger,et al. Langzeitergebnisse mit MACOP-B und Strahlentherapie bei aggressiven Non-Hodgkin-Lymphomen , 2001, Oncology Research and Treatment.
[46] M. Kneba,et al. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas]. , 2001, Onkologie.
[47] S. Pileri,et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. , 2000, Blood.
[48] M. Seto,et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. , 2000, Blood.
[49] E. Deconinck,et al. Autologous stem cell transplantation for anaplastic large‐cell lymphomas: results of a prospective trial , 2000, British journal of haematology.
[50] R. Virmani,et al. Anaplastic large cell lymphoma (CD 30+), T-phenotype, in the heart of an HIV-positive man. , 2000, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[51] G. Delsol,et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] E. Campo,et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. , 1999, Blood.
[53] T. Greiner,et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. , 1999, Blood.
[54] D. Arber,et al. Peripheral T-cell lymphoma with Toutonlike tumor giant cells associated with HIV infection: report of two cases. , 1999, The American journal of surgical pathology.
[55] G. Leverger,et al. Anaplastic Large-Cell Lymphoma in Children : Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology , 1998 .
[56] S. Pileri,et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. , 1998, The American journal of pathology.
[57] S. Pileri,et al. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. , 1998, Blood.
[58] S. Pileri,et al. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] S. Pileri,et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. , 1998, Blood.
[60] P. Gaulard,et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. , 1997, Blood.
[61] S. Pileri,et al. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. , 1997, The American journal of pathology.
[62] E. Jaffe,et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. , 1997, Blood.
[63] T. Arakawa,et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.
[64] S. Mori,et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. , 1995, Leukemia.
[65] H. Stein,et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. , 1996, Blood.
[66] F. Gherlinzoni,et al. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. , 1996, Leukemia & lymphoma.
[67] A. Bernheim,et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. , 1996, Blood.
[68] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[69] P. Brousset,et al. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. , 1995, American journal of clinical pathology.
[70] G. Delsol,et al. High incidence of Epstein–Barr virus detection in Hodgkin's disease and absence of detection in anaplastic large‐cell lymphoma in children , 1993, Histopathology.
[71] P. Scherr,et al. Non-Hodgkin's lymphoma and occupational exposure. , 1992, Cancer research.
[72] A. Hagenbeek,et al. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[73] D. Weisenburger,et al. A Case‐Control Study of Non‐Hodgkin's Lymphoma and the Herbicide 2,4‐Dichlorophenoxyacetic Acid (2, 4‐D) in Eastern Nebraska , 1990, Epidemiology.
[74] R. Warnke,et al. CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35 , 1990, British journal of haematology.
[75] D. Weisenburger. Environmental epidemiology of non-Hodgkin's lymphoma in eastern Nebraska. , 1990, American journal of industrial medicine.
[76] C. la Vecchia,et al. Occupation and lymphoid neoplasms. , 1989, British Journal of Cancer.
[77] K. Lennert,et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.
[78] Weisenburger Dd. Lymphoid malignancies in Nebraska: a hypothesis. , 1985 .
[79] D. Weisenburger. Lymphoid malignancies in Nebraska: a hypothesis. , 1985, The Nebraska medical journal.
[80] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.